| 引用本文: | 张恕芳,尹影,李晓黎,李蕊,吴坤荣,关紫菀,李妍.SGLT-2选择性抑制剂的代谢调节作用与不良反应[J].中国现代应用药学,2020,37(12):1522-1526. |
| ZHANG Shufang,YIN Ying,LI Xiaoli,LI Rui,WU Kunrong,Guan Ziwan,LI Yan.Metabolic regulation and adverse reactions of SGLT-2 selective inhibitors[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(12):1522-1526. |
|
| 本文已被：浏览 8899次 下载 4937次 |
码上扫一扫！ |
|
|
| SGLT-2选择性抑制剂的代谢调节作用与不良反应 |
|
张恕芳1, 尹影1, 李晓黎1, 李蕊2, 吴坤荣2, 关紫菀2, 李妍3
|
|
1.山东第一医科大学(山东省医学科学院)药学院, 山东 泰安 271000;2.山东大学药学院, 济南 250012;3.山东第一医科大学第一附属医院(山东省千佛山医院)药学部, 济南 250014
|
|
| 摘要: |
| 钠-葡萄糖协同转运蛋白2（sodium-glucose co-transporter-2，SGLT-2）抑制剂是一种非胰岛素依赖型的降糖药物，其作用的靶点是肾脏，可以通过抑制肾脏对葡萄糖的重吸收，使过量的葡萄糖从尿液中排出，从而发挥降低血糖的疗效。此类药物对改善血糖和血脂水平，保护胰岛细胞均有确切疗效，且不增加体质量，主要的不良反应为生殖器感染、尿路感染和酮症酸中毒。本文通过检索中国知网、万方数据库、维普数据库和PubMed数据库，综述了SGLT-2选择性抑制剂的开发过程、作用机制以及治疗糖尿病的疗效与不良反应，为临床合理用药提供参考。 |
| 关键词: 糖尿病 钠-葡萄糖协同转运蛋白-2抑制剂 代谢调节 不良反应 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.12.022 |
| 分类号:R965.1 |
| 基金项目:国家重点研发项目精准专项医疗集成应用示范体系建设项目（2017YFC0910004）；济南市科技局项目（201602171） |
|
| Metabolic regulation and adverse reactions of SGLT-2 selective inhibitors |
|
ZHANG Shufang1, YIN Ying1, LI Xiaoli1, LI Rui2, WU Kunrong2, Guan Ziwan2, LI Yan3
|
|
1.School of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of medical sciences, Tai'an 271000, China;2.School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;3.Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, the First Hospital Affiliated with Shandong First Medical University, Jinan 250014, China
|
| Abstract: |
| Sodium-glucose co-transporter-2 (SGLT-2) inhibitor is a kind of non insulin-dependent oral antidiabetic medicine. Its target is the kidney. SGLT-2 inhibitors restrain renal reabsorption of glucose so that excessive glucose can be excreted from the urine and the blood sugar is reduced. SGLT-2 inhibitors have definite efficacy on improving blood glucose and lipid level and protecting islet cells without weight gain. The main adverse reactions of SGLT-2 inhibitors are genitourinary tract infection, and ketoacidosis. By searching the medical databases including CNKI, Wanfang, Weipu and PubMed, the development, mechanisms, efficacy and adverse reactions of SGLT-2 selective inhibitors in diabetes mellitus are reviewed, so as to provide reference for clinical rational application of the medications. |
| Key words: diabetes sodium-glucose co-transporter-2 inhibitors metabolic regulation adverse reactions |
